R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Viridian Therapeutics, Inc.

R&D Spending: Ultragenyx vs. Viridian - A Decade of Innovation

__timestampUltragenyx Pharmaceutical Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 201445967000293000
Thursday, January 1, 20151147370001002000
Friday, January 1, 2016183204000888000
Sunday, January 1, 201723164400019623000
Monday, January 1, 201829399800030421000
Tuesday, January 1, 201935735500034794000
Wednesday, January 1, 202041208400028304000
Friday, January 1, 202149715300056886000
Saturday, January 1, 2022705789000100894000
Sunday, January 1, 2023648449000159765000
Loading chart...

Data in motion

R&D Spending Trends: A Decade of Innovation

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc. have shown contrasting trajectories in their R&D investments.

Ultragenyx has consistently increased its R&D spending, with a remarkable 1,300% growth from 2014 to 2023. This surge underscores their aggressive pursuit of groundbreaking therapies. In 2022, their R&D expenses peaked, reflecting a strategic push towards new drug development.

Conversely, Viridian Therapeutics, Inc. started with modest R&D investments but has shown a significant upward trend, especially in recent years. From 2014 to 2023, their R&D spending skyrocketed by over 54,000%, highlighting their evolving focus on innovation.

These trends not only reveal the companies' strategic priorities but also hint at the potential breakthroughs that could shape the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025